Abstract: In the present study, we established a practical and cost-effective high throughput screening assay, which relies on the measurement of the motility of *Caenorhabditis elegans* by infrared light-interference. Using this assay, we screened 14,400 small molecules from the “HitFinder” library (Maybridge), achieving a hit rate of 0.3%. We identified small molecules that reproducibly inhibited the motility of *C. elegans* (young adults) and assessed dose relationships for a subset of compounds. Future work will critically evaluate the potential of some of these hits as candidates for subsequent optimisation or repurposing as nematocides or nematostats. This high throughput screening assay has the advantage over many previous assays in that it is cost- and time-effective to carry out and achieves a markedly higher throughput (~10,000 compounds per week); therefore, it is suited to the screening of libraries of tens to hundreds of thousands of compounds for subsequent evaluation and development. The present phenotypic whole-worm assay should be readily adaptable to a range of socioeconomically important parasitic nematodes of humans and animals, depending on their dimensions and motility characteristics in vitro, for the discovery of new anthelmintic candidates. This focus is particularly important, given the widespread problems associated with drug resistance in many parasitic worms of livestock animals globally.

Keywords: high throughput screening; *Caenorhabditis elegans*; phenotypic screen; motility; infrared light-interference; anthelmintic

1. Introduction

The free-living nematode *Caenorhabditis elegans* is a particularly useful model for fundamental studies of metazoan organisms, in general, and for drug discovery and repurposing. This worm has been used quite extensively for investigating the nematocidal/nematostatic effects of toxins and natural or synthetic compounds [1–3]. *C. elegans* is easy to culture in the laboratory in large numbers at low cost and can be cryopreserved; it is a small worm (0.6 to 1 mm in length) and, thus, amenable to large-scale screening platforms (e.g., in 384- or 1536-well plate formats; ref. [4]). Other key advantages are the vast molecular, genetic and genomic resources, tools and extensive online information available to study its physiology and biochemistry and gene functions [5] and to identify new drug targets [6,7]. Although it appears that no anthelmintic compound discovered using *C. elegans* as a model has yet reached the clinical phase of development, some compounds that kill *C. elegans* are likely to be effective against other parasitic nematodes when compared with randomly tested molecules [8]. Therefore, the primary screening of compounds on *C. elegans* to precede or complement screening on parasitic nematodes (various developmental stages) to confirm anthelmintic activity, followed by evaluations of toxicity on cells, tissues or vertebrates/mammals can be advantageous [9]. Using such a complementary approach for drug discovery provides a foundation for ensuing studies of the modes of action,
metabolisation and detoxification of anthelmintic compounds and for understanding drug resistance mechanisms in a nematode [2,7].

Advances in imaging platforms, computer algorithms and workflows have made this ‘model organism’ a useful option for high throughput screening (e.g., [3,8,10,11]). A range of different optical imaging platforms, including the ‘complex object parametric analyzer and sorter’ (COPAS) Biosort; field-of-view ‘nematode tracking platform’ (WF-NTP); and the ‘invertebrate automated phenotyping platform’ (INVAPP), as well as high-content imaging platforms integrated with microfluidic chips, have been developed [11–16]. However, some of these platforms demand significant technical knowledge, skill and experience to set-up and calibrate, in order to achieve repeatable/reproducible results for routine use, such that “off-the-shelf”, commercially available systems can present advantages in terms of cost and time. For example, measuring motility via electrical impedance using the xCELLigence cell monitoring device [17] or with infrared light beam interference using a ‘worm tracking’ system [18,19] has shown promise for developing medium to high throughput techniques; however, a limitation of the latter approach [18,19] is that, usually, interference is measured over an extended period of hours (3 h to 17.5 h) [19–23], which can result in a substantial constraint on throughput. In the present study, we build on previous work of this ‘worm tracking’ system to establish a practical high throughput phenotypic screening platform using *C. elegans* that overcomes this limitation and is amenable to large-scale screens in an academic or industry context.

2. Results and Discussion

The present phenotypic screening assay is practical, quantitative and semi-automated. It is now being used routinely in our laboratory, and can achieve a throughput of ~10,000 compounds per week. Central to achieving this throughput has been a clear understanding of technical aspects of WMicroTracker ONE system and the settings (i.e., Modes) available. While setting up the assay, we discovered that the distinct measurement modes (settings) have a profound effect on “activity counts” (measurement of motility), and, from a critical appraisal of the literature, it seems that the WMicroTracker system has often been used without careful consideration of the settings required for screening (e.g., [19–23]). In this study, we learnt that Mode 0 (default) allows the measurement of movement within each well of each plate in a sliding time-window for the subsequent normalisation of data. In our experience, using this setting to measure nematode movement yields very low “activity counts” from individual wells and was, for us, unsuited for high throughput screening using a short data acquisition period. By contrast, Mode 1 constantly records activity counts (all movement) and gives a representative, quantitative measurement of motility, yielding high “activity counts”. By using Mode 1, we achieved a high throughput by being able to capture larval motility within the data acquisition period of 15 min, rather than a period of ≥3 h [19–23].

The motility of worms is recorded simultaneously within individual wells of the 384-well plate by interference of the infrared light beam through each well; this interference is recorded as “activity counts” (translating to motility) [18]. Measuring the motility of 50 worms within individual wells reduces experimental bias that is likely to occur when lower or higher numbers are used, and normalises the motility recorded within each well. The assay relies on the use of fresh L4s, which are readily produced immediately prior to the commencement of a screen. A critical aspect in setting up a screen is ensuring consistency in the number of worms aliquoted per well within and among plates [4]. For *C. elegans* L4s, this consistency was achievable only using both low-retention pipette tips and LB* as the suspension/dispensing medium to overcome the problem of L4s adhering to surfaces (tubes, tips and well-walls). The favourable and consistent Z'-factor (≥0.7) and signal to background (S/B) ratio (>200) show a sound performance of the assay.

Using this assay, we rapidly screened the 14,400 compounds from the HitFinder library at a concentration of 20 µM for activity on *C. elegans*. At 40 h, we identified 43 compounds that reduced worm motility by ≥70% (Table 1), equating to an overall “hit
rate” of 0.3%. Based on compound availability, we then selected a subset of compounds for further evaluation. Dose-response evaluations of HF-00014 showed a reproducible motility reduction (40 h) and an IC$_{50}$ value of 5.6 µM, and no activity for any of the three control compounds (HF-00044, HF-00045 and HF-00046) that had not been identified as hits in the primary screen (Figure 1). As there is no previous report of any of the 43 hit compounds having been tested against a nematode, current work is focused on (i) assessing the toxicity of the most promising compounds, including HF-00014 (Table 1), on HepG2 human hepatoma cells, (ii) establishing dose-response relationships for all of them, and (iii) evaluating their cellular and molecular effects on C. elegans tissues [24], as a basis for future work to undertake medicinal chemistry and structure-activity relationship (SAR) studies of the most promising scaffolds/entities.

Table 1. The 43 ‘hit’ compounds identified in the high throughput screen on Caenorhabditis elegans in the transition from L4 to the adult stage. Information regarding the compounds (code and chemical name) and the motility inhibition (≥70%) of young adult worms after 40 h of incubation with the test compound (20 µM).

| Compound Code | Chemical Name | Motility Inhibition (%) |
|---------------|---------------|-------------------------|
| HF-00001      | N,N’-bis(3,4-dichlorophenyl)urea | 100 |
| HF-00002      | 5-(methylthio)thiophene-2-carboxamide | 100 |
| HF-00003      | N2-[(dimethylamino)methylidene]-5-(2-thienyl)thiophene-2-carboxamide | 100 |
| HF-00004      | 1H-dibenzo[a,i]carbazole | 96 |
| HF-00005      | 4-amino-3-[(2-morpholinoethyl)sulfanyl][thieno][2,3-c]isothiazol-5-yl](phenyl)methanone | 92 |
| HF-00006      | 2-([4-(trifluoromethyl)phenyl]hydrazono)malononitrile | 89 |
| HF-00007      | 5-(1,3-thiazol-2-yl)-2-(2-thienyl)-7-(trifluoromethyl)pyrazolo[1,5-alpyrimidine | 88 |
| HF-00008      | 5-[2(E)-3-(6-hydroxy-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)prop-2-enylidene]-2-thioxodihydropyrimidine-4,6(1H,5H)-dione | 88 |
| HF-00009      | 3-(4-chlorophenyl)-6-(phenylmethylene)[1,3]thiazolo[2,3-c][1,2,4]triazol-5(6H)-one | 86 |
| HF-00010      | 1-[2-pyridylamino)methyl]pyrrolidine-2,5-dione | 86 |
| HF-00011      | 2-[(1-naphthylcarbonyl)amino]-3-phenylpropanoate | 85 |
| HF-00012      | (2,4-difluorophenyl)[5-(2-thienyl)-2-thienyl]methanone | 85 |
| HF-00013      | 2-(3-benzyl-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-1,3-thiazole-4-carboxylic acid | 83 |
| HF-00014      | 5-[4-(2-phenyleth-1-ynyl)phenyl]-1H-pyrazole | 83 |
| HF-00015      | 2-[[5-(trifluoromethyl)-2-pyridyl]sulfanyl]ethanohydrazide | 81 |
| HF-00016      | (5-[5-(2-thienyl)-2-thienyl]-1H-pyrazol-1-yl)-(4-methoxyphenyl)methanone | 81 |
| HF-00017      | 3,5-di(tert-butyl)-1-methyl-4-nitro-1H-pyrazole | 81 |
| HF-00018      | N’-[5-(methyl-3-phenyl-4-oxazolyl)carbonyl]-3-(2-thienyl)-1,2,4-oxadiazole-5-carboxylic acid | 81 |
| HF-00019      | 9-chloro-12H-benzo[5,6][1,4]thiazino[2,3-b]quinoxaline | 80 |
| HF-00020      | 4-phenanthro[9,10-e][1,2,4]triazin-3-ylmopholine | 80 |
| HF-00021      | 1-[2-nitro-(4-(trifluoromethyl)phenyl)piperidine | 79 |
| HF-00022      | ethyl 5-amino-1-[4-(2,5-dimethyl-1H-pyrrol-1-yl)benzoyl]-1H-pyrazole-4-carboxylate | 79 |
| HF-00023      | 2-methyl-1-phenylpropan-1-one oxime | 78 |
| HF-00024      | 7H-naptho[1,8-bc]acridin-7-one | 77 |
| HF-00025      | 2,6-di[(2-pyridylthio)methyl]pyridine | 77 |
| HF-00026      | 3-phenyl-2,3-dihydro-1,3-benzothiazol-2-imine | 75 |
| HF-00027      | 4-(tert-butyl)-N-(2-cyano-3-fluorophenyl)benzamide | 75 |
| HF-00028      | di(2,4-difluorophenyl) benzene-1,3-disulfonate | 74 |
| HF-00029      | cyclopentane-1,2-dicarboxylic acid | 74 |
| HF-00030      | 5,7-dimethyl[1,2,4]triazolo[1,5-alpyrimidine-2-thiol | 74 |
| HF-00031      | N-[2-[4-(trifluoromethyl)-2-pyrimidinyl]piperazino]ethylbenzamide | 74 |
| HF-00032      | [3-(2-chlorophenyl)-5-methylisoxazol-4-yl][4-fluorophenyl]methanone | 73 |
| HF-00033      | 2-([4-(1,3-benzothiazol-2-yl)anilino]-2-o xoethyl)sulfanyl)acetic acid | 73 |
Table 1. Cont.

| Compound Code | Chemical Name                                                   | Motility Inhibition (%) |
|---------------|-----------------------------------------------------------------|-------------------------|
| HF-00034      | 3-(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-1-{(4-methoxyphenyl)sulfonyl}-1H-pyrazole | 73                      |
| HF-00035      | 2-benzo[b]thiophen-3-yl-3-(4-fluorophenyl)acrylonitrile         | 73                      |
| HF-00036      | diethyl 4-{(3-methoxyphenyl)thio}pyridine-2,6-dicarboxylate      | 72                      |
| HF-00037      | N1-(3-fluorophenyl)-2-[5-(4-nitrophenyl)-2-furyl]methylidene/hydrazine-1-carbothioamide | 72                      |
| HF-00038      | 4-bromo-2-(4-bromoanilin-1)-1,2-dihydrosoquinolin-1-one         | 72                      |
| HF-00039      | 2-chloro-4-fluoro-N-(3-methoxyphenyl)-1H-pyrazol-3-ylbenzamide  | 72                      |
| HF-00040      | N1-[3-(trifluoromethyl)phenyl]-2-(3,3-dithiopropanoyl)hydrazine-1-carboxamide | 72                      |
| HF-00041      | 2-(1H-indol-3-yl)-3-[4-(trifluoromethyl)phenyl]acrylonitrile     | 72                      |
| HF-00042      | ethyl 3-amino-4-(methylamino)benzoate                           | 71                      |
| HF-00043      | 2-(3-methoxybenzyl)-5-[5-(2-thienyl)-2-thienyl]-1,3,4-oxadiazole | 70                      |

Figure 1. Dose-response curves for hit compound HF-00014, two positive control compounds (monepantel and moxidectin) and three non-hit compounds (HF-00044, HF-00045 and HF-00046; negative reference controls) assessed in 96-well plates for the inhibition of motility of young adult Caenorhabditis elegans at 40 h. Each data point represents three replicates, with the mean ± standard error of the mean (SEM) values indicated. As expected, compound HF-00014, identified in the primary screen against C. elegans (in the transition from L4 to the adult stage) and achieving 83% motility inhibition (see Table 1), exhibited a dose-dependent effect. IC_{50} values were 0.06 and 0.03 for monepantel and moxidectin, respectively, and 5.6 µM for HF-00014. na = not applicable.

In conclusion, the screening platform established is practical and straightforward to set up, costing ~US$65,000, with the majority of this expense relating to the purchase of two WMicroTracker ONE instruments (at US $15,000 each), a semi-automated liquid handling robot (at US $30,000) and an incubator (e.g., Heratherm IMP180, Thermo Fisher Scientific, Waltham, MA, USA; at US $5000) for the culturing of C. elegans. This system—now routinely used in our laboratory—meets a high standard and is suited for large-scale screens to identify new chemical entities with nematocidal or nematostatic activities [25]. Screening on C. elegans provides the exciting prospect of eventually exploring the mechanisms of action of lead candidates and the development of resistance to them in vitro, particularly given the availability of extensive resources and functional genomics platforms for this free-living nematode. Our plan now is to expand the use of the present screening platform to parasitic worms of socioeconomic importance, including the barber’s pole worm (Haemonchus contortus), Ascaris and/or hookworms. This focus is of paramount importance, given the widespread problems with anthelmintic resistance in nematode populations of livestock animals.
3. Materials and Methods

3.1. Preparation of C. elegans Larvae for Screening

A wildtype Caenorhabditis elegans strain (Bristol N2) was maintained in the laboratory under standard conditions at 20 °C on nematode growth medium (NGM) agar plates [25], seeded with Escherichia coli OP50 as a food source. This C. elegans strain was grown and maintained according to well-established protocols [26,27].

C. elegans was synchronised using an established method [28]. Gravid adult worms were collected from NGM plates and washed in sterile M9 buffer and then treated with 1% bleach for 4–9 min at room temperature (22–24 °C) to release eggs [26]. Eggs were immediately collected, washed four times in M9 buffer by centrifugation at 500 × g (2 min) at the same temperature and examined microscopically. Then, eggs were incubated in M9 buffer under slight agitation for ~24 h, allowing first-stage larvae (L1s) to hatch and enter diapause. Approximately 36 h before setting up compound-screening, arrested L1s were pipetted on to NGM agar plates (10 cm) previously seeded with 500 µL of E. coli OP50 (~1000 larvae per plate). Plates were incubated at 20 °C to allow worms to synchronously develop to fourth-stage larvae (L4s). On the day of compound-screening, fourth-stage larvae (L4s) were collected from culture plates and washed twice in M9 buffer by centrifugation at 500 × g (2 min) to remove E. coli OP50. L4s were immediately suspended in Luria-Bertani broth [29] containing 100 IU/mL of penicillin, 100 µg/mL of streptomycin and 0.25 µg/mL of amphotericin B (Thermo Fisher Scientific, Waltham, MA, USA) (called LB*) and diluted to a worm density of 2500 L4s per mL.

3.2. High Throughput Screening of Compounds for Motility Reduction of C. elegans

The “HitFinder” (HF) library, containing 14,400 (synthetic) small molecular compounds, was curated by Maybridge (Thermo Fisher Scientific, Waltham, MA, USA). These compounds were supplied at a concentration of 10 mM in 100% dimethyl sulfoxide (DMSO). Using a semi-automated liquid handling robot (VIAFLO ASSIST PLUS, Integra Biosciences, Zizers, Switzerland), compounds were individually diluted to 20 µM in LB* containing 0.2% (v/v) DMSO and subsequently dispensed in 20 µL into the wells of sterile 384-well flat bottom microtitre plates (cat. no. 3680; Corning, Corning, NY, USA); 320 compounds were arrayed on each plate, with 16 wells being negative controls (with LB* + 0.2% DMSO) and four wells containing each monepantel (Zolvix; Elanco, NY, USA), moxidectin (Cydectin; Virbac, Carros, France), monepantel/abamectin (Zolvix Plus; Elanco, NY, USA) and compound MIPS-0018666 (abbreviated here as M-666; see [30]) as positive controls (20 µM). Following the dilution and dispensing of compounds into plates, 50 C. elegans L4s in 20 µL of LB* were transferred to individual wells; after this step, the final concentrations were 20 µM of the test- or positive-control compound; and 0.2% of DMSO. During dispensing, L4s were maintained in a homogenous suspension using a constant stream of bubbles produced using an aquarium pump (H2Pro, Melbourne, Australia). Plates containing C. elegans L4s were placed in an incubator (Heratherm, model no. IMP180, Thermo Fisher Scientific, Waltham, MA, USA) at 20 °C. After 40 h of incubation with compounds (20 µM), the motility of young adult C. elegans (following transition from L4) in individual wells of individual plates was measured for 15 min by infrared light beam-interference [18] using a WMicroTracker ONE instrument (Phylumtech, Sunchales, Argentina; details on the instrument and associated technology are available via http://www.phylumtech.com/home/en/home-en/ (accessed on 8 July 2021) employing the Mode 1_threshold average setting (described in the user manual for this instrument). Raw data (i.e., ‘activity counts’) were normalised using measurements for the positive (M-666) and negative (LB* + 0.2% DMSO) controls, in order to remove plate-to-plate variation by calculating the percentage of motility using the program GraphPad Prism v.9.1.0 (GraphPad Software, San Diego, CA, USA). A compound was recorded as a “hit” (i.e., active) if it reduced larval motility by ≥70%. The performance of this assay was continually monitored over time using the Z’-factor [31], which was calculated using data for the negative (DMSO) and the M-666 controls on individual plates (n = 43). Assays with a ‘sound’ performance achieve a Z’-factor of 0.5 to 1; the present assay
consistently achieved $\geq 0.7$. We also measured the S/B ratio [32] using data from the same control wells; this ratio was consistently $\geq 200$.

3.3. Dose-Response Assay

Dose-response relationships were established to estimate IC$_{50}$ values for selected compounds against *C. elegans*. With reference to two positive control compounds (monepantel and moxidectin), IC$_{50}$ values were established for hit compounds by 10-fold serial dilution, starting at a concentration of 100 $\mu$M (18-points; in 50 $\mu$L of LB; 100 $\mu$M to 0.76 nM), in 96-well plates (cat. no. 3596; Corning, Corning, NY, USA) with larvae dispensed in 50 $\mu$L at a density of 100 *C. elegans* L4s per well. After incubation at 20 °C, the motility of young adult worms in individual wells was measured at 40 h of incubation with the compound. Compound concentrations were log$_{10}$-transformed, and fitted using a variable slope four-parameter equation, constraining the highest value to 100%, employing a least squares (ordinary) fit model using the GraphPad Prism software v9.1.0. Compounds were tested in triplicate. For statistical analysis of larval motility, a one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test or an unpaired $t$-test was used to establish statistically significant differences.

**Author Contributions:** Conceptualisation, R.B.G. and A.C.T.; methodology, A.C.T. and J.J.B.; validation, A.C.T. and J.J.B.; formal analysis, R.B.G., A.C.T. and J.J.B.; investigation, A.C.T.; resources, A.C.T., J.J.B. and P.R.B.; data curation, A.C.T. and J.J.B.; writing—original draft preparation, R.B.G., A.C.T. and J.J.B.; writing—review and editing, A.C.T., J.J.B., P.R.B., A.J. and R.B.G.; visualisation, A.C.T.; supervision, R.B.G.; project administration, R.B.G. and A.C.T.; funding acquisition, R.B.G. and A.J. All authors have read and agreed to the published version of the manuscript.

**Funding:** The present study was supported by the Australian Research Council (ARC), Phylumtech (Argentina) and Yourgene Health p/l (Singapore).

**Institutional Review Board Statement:** The study was conducted in accordance with the institutional animal ethics guidelines (permit no. 1714374; The University of Melbourne).

**Data Availability Statement:** Data are within the article.

**Conflicts of Interest:** The authors declare no conflict of interest and the funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**Sample Availability:** Samples of the compounds are not available from the authors.

**References**

1. Geary, T.G.; Thompson, D.P. *Caenorhabditis elegans*: How good a model for veterinary parasites? *Vet. Parasitol.* 2001, 101, 371–386. [CrossRef]

2. Holden-Dye, L.; Walker, R.J. Anthelmintic drugs and nematicides: Studies in *Caenorhabditis elegans*. In *WormBook: The Online Review of C. elegans Biology*; The C. elegans Research Community: Pasadena, CA, USA, 2014; pp. 1–29.

3. Sepúlveda-Crespo, D.; Reguera, R.M.; Rojo-Vázquez, F; Balaña-Fouce, R.; Martinez-Valladares, M. Drug discovery technologies: *Caenorhabditis elegans* as a model for anthelmintic therapeutics. *Med. Res. Rev.* 2020, 40, 1715–1753. [CrossRef] [PubMed]

4. O’Reilly, L.P.; Luke, C.J.; Perlmutter, D.H.; Silverman, G.A.; Pak, S.C. *C. elegans* in high-throughput drug discovery. *Adv. Drug Deliv. Rev.* 2014, 69, 247–253. [CrossRef]

5. Harris, T.W.; Arnaboldi, V; Cain, S.; Chan, J.; Chen, W.J.; Cho, J.; Davis, P.; Gao, S.; Grove, C.A.; Kishore, R.; et al. WormBase: A modern model organism information resource. *Nucleic Acids Res.* 2020, 48, D762–D767. [CrossRef] [PubMed]

6. Salinas, G.; Risi, G. *Caenorhabditis elegans*: Nature and nurture gift to nematode parasitologists. *Parasitology* 2018, 145, 979–987. [CrossRef]

7. Hahnel, S.R.; Dilks, C.M.; Heisler, I.; Andersen, E.C.; Kulke, D. *Caenorhabditis elegans* in anthelmintic research—Old model, new perspectives. *Int. J. Parasitol. Drugs Drug Resist.* 2020, 14, 237–248. [CrossRef]

8. Burns, A.R.; Luciani, G.M.; Musso, G.; Bagg, R.; Yeo, M.; Zhang, Y.; Rajendran, L.; Glavín, J.; Hunter, R.; Redman, E.; et al. *Caenorhabditis elegans* is a useful model for anthelmintic discovery. *Nat. Commun.* 2015, 6, 7485. [CrossRef]

9. Keiser, J. *Is Caenorhabditis elegans* the magic bullet for anthelmintic drug discovery? *Trends Parasitol.* 2015, 31, 455–456. [CrossRef]

10. Geary, T.G.; Sakanari, J.A.; Caffrey, C.R. Anthelmintic drug discovery: Into the future. *J. Parasitol.* 2015, 101, 125–133. [CrossRef]
11. Partridge, F.A.; Brown, A.E.; Buckingham, S.D.; Willis, N.J.; Wynne, G.M.; Forman, R.; Else, K.J.; Morrison, A.A.; Matthews, J.B.; Russell, A.J.; et al. An automated high-throughput system for phenotypic screening of chemical libraries on C. elegans and parasitic nematodes. *Int. J. Parasitol. Drugs Drug Resist.* 2018, 8, 8–21. [CrossRef]

12. Burns, A.R.; Kwok, T.C.Y.; Howard, A.; Houston, E.; Johanson, K.; Chan, A.; Cutler, S.R.; McCourt, P.; Roy, P.J. High-throughput screening of small molecules for bioactivity and target identification in *Caenorhabditis elegans*. *Nat. Protoc.* 2006, 1, 1906–1914. [CrossRef]

13. Mondal, S.; Hegarty, E.; Martin, C.; Gökçê, S.K.; Ghorashian, N.; Ben-Yakar, A. Large-scale microfluidics providing high-resolution and high-throughput screening of *Caenorhabditis elegans* poly-glutamine aggregation model. *Nat. Commun.* 2016, 7, 13023. [CrossRef] [PubMed]

14. Weeks, J.C.; Roberts, W.M.; Robinson, K.J.; Keaney, M.; Vermeire, J.J.; Urban, J.F.; Lockery, S.R.; Hawdon, J.M. Microfluidic platform for electrophysiological recordings from host-stage hookworm and *Ascaris suum* larvae: A new tool for anthelmintic research. *Int. J. Parasitol. Drugs Drug Resist.* 2016, 6, 314–328. [CrossRef] [PubMed]

15. Atakan, H.B.; Xiang, R.; Cornaglia, M.; Mouchiroud, L.; Katsyuba, E.; Auwerx, J.; Gijs, M.A.M. Automated platform for long-term culture and high-content phenotyping of single *C. elegans* worms. *Sci. Rep.* 2019, 9, 14340. [CrossRef] [PubMed]

16. Koopman, M.; Peter, Q.; Seinstra, R.I.; Perni, M.; Dobson, C.M.; Knowles, T.P.; Nollen, E.A.A. Assessing motor-related phenotypes of *Caenorhabditis elegans* with the wide field-of-view nematode tracking platform. *Nat. Protoc.* 2020, 15, 2071–2106. [CrossRef]

17. Simonetta, S.H.; Golombek, D.A. An automated tracking system for *Caenorhabditis elegans* locomotor behavior and circadian studies application. *J. Neurosci. Methods* 2007, 161, 273–280. [CrossRef]

18. Risi, G.; Aguilera, E.; Ladós, E.; Suárez, G.; Carrera, I.; Álvarez, G.; Salinas, G. *Caenorhabditis elegans* infrared-based motility assay identified new hits for nematicide drug development. *Vet. Sci.* 2019, 6, 29. [CrossRef]

19. Liu, M.; Landuyt, B.; Aertsens, J.; Gijssels, H.; Geys, S.L.; Landuyt, B.; Alps, M.; Aertsens, J.; Luyten, W. Screening of a drug repurposing library with a nematode motility assay identifies promising anthelmintic hits against *Cooperia oncophora* and other ruminant parasites. *Vet. Parasitol.* 2018, 265, 15–18. [CrossRef]

20. Liu, M.; Kipanga, P.; Mai, A.H.; Dhondt, I.; Braeckman, B.P.; Borggraeve, W.D.; Luyten, W. Bioassay-guided isolation of three anthelmintic compounds from *Warburgia ugandensis* Sprague subspecies *ugandensis*, and the mechanism of action of polygodial. *Int. J. Parasitol.* 2018, 48, 833–844. [CrossRef]

21. Panda, S.K.; Padhi, L.; Leyssen, P.; Liu, M.; Neyts, J.; Luyten, W. Antimicrobial, anthelmintic, and antiviral activity of plants traditionally used for treating infectious disease in the similipal biosphere reserve, Odisha, India. *Front. Pharmacol.* 2017, 8, 658. [CrossRef]

22. Puyvelde, L.V.; Liu, M.; Veryser, C.; Borggraeve, W.M.D.; Mungarulire, J.; Mukazayire, M.J.; Luyten, W. Active principles of *Tetradenia riparia*. IV. anthelmintic activity of 8(14),15-sandaracopimaradiene-7α,18-diol. *J. Ethnopharmacol.* 2018, 216, 229–232. [CrossRef]

23. Barnett, R.E.; Bailey, D.C.; Hatfield, H.E.; Fitisanakis, V.A. Chapter 26—*Caenorhabditis elegans*: A Model Organism for Nutraceutical Safety and Toxicity Evaluation. In *Nutraceuticals*; Gupta, R.C., Ed.; Academic Press: Boston, MA, USA, 2016; pp. 341–354.

24. Clare, R.H.; Bardelle, C.; Harper, P.; Hong, W.D.; Börjesson, U.; Johnston, K.L.; Collier, M.; Myhill, L.; Cassidy, A.; Plant, D.; et al. Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides. *Nat. Commun.* 2019, 10, 11. [CrossRef]

25. Sterinagle, T. Maintenance of *C. elegans*. In *WormBook: The Online Review of C. elegans Biology*; The C. elegans Research Community: Pasadena, CA, USA, 2006.

26. Brenner, S. The genetics of *Caenorhabditis elegans*. *Genetics* 1974, 77, 71–94. [CrossRef]

27. Porta-de-la-Riva, M.; Fontrodona, L.; Villanueva, A.; Cerón, J. Basic *Caenorhabditis elegans* methods: Synchronization and observation. *J. Vis. Exp.* 2012, 64, 4019. [CrossRef]

28. Bentani, G. Studies on lysogenesis. I. The mode of phage liberation by lysogenic *Escherichia coli*. *J. Bacteriol.* 1951, 62, 293–300. [CrossRef]

29. Le, T.G.; Kundu, A.; Ghoshal, A.; Nguyen, N.H.; Preston, S.; Jiao, Y.; Ruan, B.; Xue, L.; Huang, F.; Keiser, J.; et al. Optimization of novel 1-methyl-1 h-pyrazole-5-carboxamides leads to high potency larval development inhibitors of the barber’s pole worm. *J. Med. Chem.* 2018, 61, 10875–10894. [CrossRef] [PubMed]

30. Zhang, J.H.; Chung, T.D.; Oldenburg, K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J. Biomed. Screen.* 1999, 4, 67–73. [CrossRef] [PubMed]

31. Sui, Y.; Wu, Z. Alternative statistical parameter for high-throughput screening assay quality assessment. *J. Biomed. Screen.* 2007, 12, 229–234. [CrossRef] [PubMed]